We are pleased to announce our investment in Hologenomix, a biotechnology startup advancing non-invasive cancer diagnostics through innovative cell-free nucleic acids (cfDNA and cfRNA) extraction technology. By improving how cfDNA and cfRNA are isolated from urine samples, Hologenomix is paving the way for more accessible, accurate, and patient-friendly cancer detection and monitoring.

‍

Liquid biopsy has emerged as a promising alternative to traditional cancer diagnostics, enabling detection and monitoring through bodily fluids rather than invasive tissue biopsies. However, current approaches face a major limitation: extracting sufficient high-quality cfDNA and cfRNA remains challenging, particularly from urine samples. This bottleneck restricts the sensitivity and reliability of downstream molecular analyses, limiting the full potential of liquid biopsy in clinical practice.

‍

‍To address this challenge, Hologenomix has developed a proprietary High-efficiency Flow eXtraction (HFX) workflow that significantly improves both the yield and quality of nucleaic acids. By enabling the processing of larger sample volumes while preserving the natural characteristics of DNA fragments, the technology allows for more reliable molecular analysis without the need for PCR amplification. This breakthrough has the potential to support earlier cancer detection, improve treatment monitoring, and reduce the need for invasive follow-up procedures.

‍

‍With this investment, Hologenomix will further develop its HFX workflow, build a dedicated hardware platform, and initiate clinical validation studies in collaboration with leading academic hospitals. These steps are essential to bringing the technology closer to real-world application in molecular diagnostics and liquid biopsy.

‍

‍The company is led by Eric van der Toorn, David Calderón Franco, and Thomas Abeel. Together, they combine deep expertise in bioinformatics, biotechnology, and molecular diagnostics, supported by a strong network in the life sciences and healthcare sectors.

‍

‍At Graduate Ventures, we believe in the power of breakthrough technologies to transform healthcare. We are proud to support Hologenomix in their mission to make cancer diagnostics less invasive, more accessible, and more effective.

‍

‍Interested in learning more about Hologenomix? Visit their website!

‍